Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus (Q36892807)

16 August 2017

1 reference

title

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus (English)

1 reference

16 August 2017

1 reference

Alissa K Langley

1

1 reference

16 August 2017

Terri J Suffoletta

series ordinal

2

1 reference

16 August 2017

Heath R Jennings

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

27

1 reference

16 August 2017

8

1 reference

16 August 2017

1163-1180

1 reference

Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S.

16 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Deconstructing type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Cellular mechanisms of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Beta- and alpha-cell dysfunction in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

The burden of treatment failure in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

A systematic review of adherence with medications for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

The incretin concept today

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

What do we know about the secretion and degradation of incretin hormones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Gut peptides and type 2 diabetes mellitus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

CD26: a surface protease involved in T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Expression of CD26 (dipeptidyl peptidase IV) on memory and naive T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Proline-dependent structural and biological properties of peptides and proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Diet and Exercise Among Adults With Type 2 Diabetes: Findings from the Third National Health and Nutrition Examination Survey (NHANES III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.8.1163

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.8.1163

1 reference

release_my5imslaxjefjcoirpmpie4a7y

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/my5imslaxjefjcoirpmpie4a7y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference